Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss
Authors not listed
Amgen · 2010
Abstract
Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
Anonymous. (2010). A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss. <em>Amgen</em>. https://clinicaltrials.gov/study/NCT00975104
Vancouver
Anonymous. A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss. Amgen. 2010.
BibTeX
@misc{anon2010ARando,
title = {A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss},
author = {Anonymous},
journal = {Amgen},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
AbbVie (prior sponsor, Abbott) 2009
Open access · US-GOV
A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
SIPO Biotechnology Co. Ltd. 2027
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.
Merck Sharp & Dohme LLC 2007
Open access · US-GOV
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia
Vigil Neuroscience, Inc. 2023
Open access · US-GOV
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Cognition Therapeutics 2023
Open access · US-GOV